Effect of mycophenolate sodium in scleroderma-related interstitial lung disease

Clinical Rheumatology

Volumn 30, Issue 11, 2011, Pages 1393-1398

  Simeón Aznar, Carmen Pilar ^a   Fonollosa Plá, Vicent ^a   Tolosa Vilella, Carles ^b   Selva O'Callaghan, Albert ^a   Solans Laqué, Roser ^a   Vilardell Tarrés, Miquel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Hospital Universitari Parc Taulí   (Spain)

Author keywords

Interstitial lung disease; Mycophenolate sodium; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; MYCOPHENOLIC ACID; PREDNISONE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; SCLERODERMA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 80755163187     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1823-1     Document Type: Article

References (41)

1. B White 2003 Interstitial lung disease in scleroderma Rheum Dis Clin N Am 29 371 390 10.1016/S0889-857X(03)00025-5 (Pubitemid 36765126)
2. S Jacobsen S Ullman GQ Shen A Wiik P Halberg 2001 Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis J Rheumatol 28 2454 2459 11708418 1:STN:280:DC%2BD3Mnmt1Oqtg%3D%3D (Pubitemid 33031976)
3. V Steen TA Medsger Jr 2000 Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum 43 2437 2444 11083266 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U 1:STN:280:DC%2BD3M%2FktFequw%3D%3D
4. R Altman TA Medsger Jr D Bloch BA Michel 1991 Predictors of survival in systemic sclerosis (scleroderma) Arthritis Rheum 34 403 413 1901491 10.1002/art.1780340405 1:STN:280:DyaK3M7ptVWlsg%3D%3D
5. R Hubbard A Venn 2002 The impact of coexisting connective tissue disease on survival on patients with fibrosing alveolitis Rheumatology (Oxford) 41 676 679 10.1093/rheumatology/41.6.676 1:STN:280:DC%2BD38zgs1GmsA%3D%3D (Pubitemid 34618887)
6. P Lee P Langevitz CA Alderdice M Aubrey PA Baer M Baron, et al. 1992 Mortality in systemic sclerosis (scleroderma) Q J Med 298 139 148
7. RM Silver JH Warrick M Kinsella LS Staudt MH Baumann C Strange 1993 Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease J Rheumatol 20 838 844 8336309 1:STN:280:DyaK3szivFKktA%3D%3D (Pubitemid 23158478)
8. B White WC Moore FM Wigley Xiao Hui Qing RA Wise 2000 Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 132 947 954 10858177 1:CAS:528:DC%2BD3cXkslylsb8%3D (Pubitemid 30397594)
9. DP Tashkin R Elashoff PJ Clements Scleroderma Lung Study 2006 Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655 2666 16790698 10.1056/NEJMoa055120 1:CAS:528:DC%2BD28XmtFSgtLs%3D
10. R Hoyles R Ellis J Wellsbury B Lees P Newlands NS Goh, et al. 2006 A multicenter, prospective, randomised, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 54 3962 3970 17133610 10.1002/art.22204 1:CAS:528:DC%2BD2sXktlalug%3D%3D (Pubitemid 44955900)
11. EM Davas C Pepas M Maragou E Alvanou D Hondros PC Dantis 1999 Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma Clin Rheumatol 18 455 461 10638770 10.1007/s100670050138 1:STN:280:DC%2BD3c7gt1ejug%3D%3D (Pubitemid 30014164)
12. G Varai L Earle SA Jiménez RM Steinert J Varga 1998 A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease J Rheumatol 25 1325 1329 9676764 1:CAS:528:DyaK1cXkslWjsLw%3D (Pubitemid 28312350)
13. I Pakas JP Ioannidis K Malagari FN Skopouli HM Moutsopoulos PG Vlachyiannopoulos 2002 Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease J Rheumatol 29 298 304 11842824 1:CAS:528:DC%2BD38XhsF2iu78%3D (Pubitemid 34118777)
14. R Giacomelli G Valentini F Salsano P Cipriani P Sambo ML Conferti, et al. 2002 Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis J Rheumatol 29 731 736 11950014 1:CAS:528:DC%2BD38XjtFGltLw%3D (Pubitemid 34303867)
15. B Griffiths S Miles H Moss R Robertson D Veale P Emery 2002 Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function J Rheumatol 29 2371 2378 12415594 1:CAS:528:DC%2BD38XptVGgt7s%3D (Pubitemid 35266028)
16. G Mittal Z Udwadia VR Joshi 2003 Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis J Rheumatol 30 1121 1122 12734923 (Pubitemid 36529648)
17. P Airò E Danieli G Parrinello Frassi I Cavazzana M Scarsi, et al. 2004 Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results Clin Exp Rheumatol 22 573 578 15485010 (Pubitemid 39302934)
18. O Kowal-Bielecka K Kowal J Rojewska A Bodzenta-Lukaszyk Z Siergiejko M Sierakowska, et al. 2005 Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations Ann Rheum Dis 64 1343 1346 16100339 10.1136/ard.2004.033076 1:STN:280:DC%2BD2MvjtFKgsQ%3D%3D (Pubitemid 41206254)
19. G Yiannopoulos V Pastromas I Antonopoulos G Katsiberis G Kalliolias SN Liossis, et al. 2007 Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease Rheumatol Int 27 357 361 17021713 10.1007/s00296-006-0217-1 1:CAS:528:DC%2BD2sXkslansA%3D%3D (Pubitemid 46122279)
20. CP Simeón V Fonollosa C Tolosa A Selva R Solans E Palliza, et al. 2008 Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis related interstitial lung disease: a long term study Open Respir Med J 2 39 45 10.2174/1874306400802010039
21. D Tahskhin R Elashoff P Clements SLR group 2007 Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease Am J Respir Crit Care Med 176 1026 1034 10.1164/rccm.200702-326OC (Pubitemid 350127847)
22. SN Liossis A Bounas AP Andonopoulos 2006 Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease Rheumatology (Oxford) 45 1005 1008 10.1093/rheumatology/kei211 1:CAS:528:DC%2BD28Xotl2ku7w%3D (Pubitemid 44283057)
23. JJ Swigris AL Olson A Fischer DA Lynch GP Cosgrove SK Frankel, et al. 2006 Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease Chest 130 30 36 16840379 10.1378/chest.130.1.30 1:CAS:528:DC%2BD28Xot1KjtL8%3D (Pubitemid 44116838)
24. AC Zamora PJ Wolters HR Collard K Connolly B Elicker W Webb, et al. 2008 Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease Respir Med 102 150 155 17822892 10.1016/j.rmed.2007.07.021 (Pubitemid 350151821)
25. A Gerbino C Goss J Molitor 2008 Effect of mycohenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease Chest 133 455 460 18071023 10.1378/chest.06-2861 1:CAS:528:DC%2BD1cXjtFemsLg%3D (Pubitemid 351272405)
26. A Koutroumpas A Ziogas I Alexiou G Barouta L Sakkas 2010 Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease Clin Rheumatol 10 1167 1168 10.1007/s10067-010-1498-z
27. M Vanthuyne D Bockmans R Westhovens F Roufosse E Cogan E Coche, et al. 2007 A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis Clin Exp Rheumatol 25 287 292 17543155 1:STN:280: DC%2BD2szjtF2msg%3D%3D (Pubitemid 46851433)
28. AC Allison EM Eugui 2000 Mycophenolate mofetil and its mechanism of action Immunopharmacology 47 85 118 10878285 10.1016/S0162-3109(00)00188-0 1:CAS:528:DC%2BD3cXktlKkt7o%3D (Pubitemid 30394534)
29. GB Appel J Radhakrishnan EM Ginzler 2005 Use of mycophenolate mofetil in autoimmune and renal diseases Transplantation 80 2 Suppl S265 S271 16251859 10.1097/01.tp.0000186389.19911.9c 1:CAS:528:DC%2BD2MXhtFGhsL7L (Pubitemid 41552913)
30. H Shimizu M Takahashi S Takeda S Inoue J Fujishiro Y Hakamata, et al. 2004 Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation Transplantation 77 1661 1667 15201664 10.1097/01.TP.0000127592.13707.B6 1:CAS:528:DC%2BD2cXkvVOjtbk%3D (Pubitemid 38780531)
31. H Guo JC Leung LY Chan, et al. 2005 Modulation of intrapulmonary TGF- expression by mycophenolate mofetil in lupus prone MRL/pr mice Lupus 14 583 592 16175929 10.1191/0961203305lu2170oa 1:CAS:528:DC%2BD2MXhtFSnsLvN (Pubitemid 41296994)
32. K Budde J Curtis G Knoll 2004 Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study Am J Transplantation 4 237 243 10.1046/j.1600-6143.2003.00321.x 1:CAS:528:DC%2BD2cXitleisbo%3D (Pubitemid 38248527)
33. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee 1980 Preliminary criteria for the classification of systemic sclerosis Arthritis Rheum 23 581 590 10.1002/art.1780230510
34. EC LeRoy C Black R Fleishmayer S Jablonska T Krieg TA Medsger, et al. 1988 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J Rheumatol 15 202 208 3361530 1:STN:280:DyaL1c3gtVWnsg%3D%3D
35. CP Simeón L Armadans V Fonollosa M Vilardell J Candell C Tolosa, et al. 1997 Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis Ann Rheum Dis 56 723 728 9496151 10.1136/ard.56.12.723 (Pubitemid 28064838)
36. J Roca J Sanchis A Agustí-Vidal F Segarra D Navajas R Rodríguez-Roisin, et al. 1986 Spirometric reference values from a Mediterranean population Bull Eur Physiopathol Respir 22 217 224 3730638 1:STN:280:DyaL283ntVCrtg%3D%3D (Pubitemid 16116729)
37. American Thoracic Society (ATS) 2000 Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS) Am J Respir Crit Care Med 161 646 664
38. KM Antoniou AU Wells 2008 Scleroderma lung disease: evolving understanding in light of newer studies Curr Opin Rheumatol 20 686 691 18946329 10.1097/BOR.0b013e3283126985 1:STN:280:DC%2BD1cnotFOjsQ%3D%3D
39. J Behr DE Furst 2008 Pulmonary function tests Rheumatology (Oxford) 47 Suppl 5 v65 v67 10.1093/rheumatology/ken313
40. SI Nihtyanova GM Brogh CM Black CP Denton 2007 Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis Rheumatology (Oxford) 46 442 445 10.1093/rheumatology/kel244 1:CAS:528:DC%2BD2sXhvFWltbg%3D (Pubitemid 46344656)
41. Derk E Grace M Shenin M Naik S Schultz W Xiong, et al. 2009 Rheumatology 48 1595 1599 19846575 10.1093/rheumatology/kep295 1:CAS:528:DC%2BC3cXisVOhsrw%3D